tiprankstipranks
Advertisement
Advertisement

GILD Stock Latest News

Gilead downgraded at Leerink on long-term headwinds to HIV PrEP expansion
The FlyGilead downgraded at Leerink on long-term headwinds to HIV PrEP expansion
11h ago
GILD
Gilead downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
Gilead downgraded to Market Perform from Outperform at Leerink
11h ago
GILD
Gilead’s Zamzetoclax Trial Update: What a Terminated Phase 1 Means for GILD Investors
PremiumCompany Announcements
Gilead’s Zamzetoclax Trial Update: What a Terminated Phase 1 Means for GILD Investors
4d ago
GILD
Gilead Targets Long-Acting HIV Regimens With New Injectable Study
PremiumCompany Announcements
Gilead Targets Long-Acting HIV Regimens With New Injectable Study
5d ago
GILD
Gilead Expands Oncology Ambitions With New Denikitug Trial in Tough GI Cancers
PremiumCompany Announcements
Gilead Expands Oncology Ambitions With New Denikitug Trial in Tough GI Cancers
11d ago
GILD
Gilead Targets Long-Acting HIV Control With New Injectable Study Versus Biktarvy
PremiumCompany AnnouncementsGilead Targets Long-Acting HIV Control With New Injectable Study Versus Biktarvy
11d ago
GILD
Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley
Premium
The Fly
Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley
11d ago
GILD
LKFT
Gilead price target lowered to $166 from $168 at Morgan Stanley
Premium
The Fly
Gilead price target lowered to $166 from $168 at Morgan Stanley
13d ago
GILD
Early notable gainers among liquid option names on July 7th
PremiumThe Fly
Early notable gainers among liquid option names on July 7th
14d ago
CHTR
DASH
Gilead price target lowered to $156 from $157 at Truist
PremiumThe Fly
Gilead price target lowered to $156 from $157 at Truist
14d ago
GILD
Gilead price target lowered to $120 from $122 at RBC Capital
PremiumThe Fly
Gilead price target lowered to $120 from $122 at RBC Capital
14d ago
GILD
Citizens biotech analyst holds an analyst/industry conference call
PremiumThe Fly
Citizens biotech analyst holds an analyst/industry conference call
15d ago
ALLO
CLLS
Midday Fly By: SK Hynix targets U.S. listing, Lockheed to acquire Ultra Maritime
PremiumThe FlyMidday Fly By: SK Hynix targets U.S. listing, Lockheed to acquire Ultra Maritime
15d ago
S
BA
Okta upgraded, Datadog downgraded: Wall Street’s top analyst calls
Premium
The Fly
Okta upgraded, Datadog downgraded: Wall Street’s top analyst calls
15d ago
M
S
Gilead upgraded to Buy from Hold at HSBC
Premium
The Fly
Gilead upgraded to Buy from Hold at HSBC
15d ago
GILD
Citizens biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens biotech analysts hold an analyst/industry conference call
18d ago
ALLO
CLLS
Unusually active option classes on open June 30th
PremiumThe Fly
Unusually active option classes on open June 30th
21d ago
CE
CL
Analyst Reiterates Buy on Gilead, Keeping Yeztugo‑Driven Outlook Intact with Unchanged $168 Price Target
PremiumRatings
Analyst Reiterates Buy on Gilead, Keeping Yeztugo‑Driven Outlook Intact with Unchanged $168 Price Target
21d ago
GILD
Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy
PremiumThe Fly
Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy
26d ago
MRK
GILD
FDA approves Gilead’s Trodelvy for two indications
PremiumThe FlyFDA approves Gilead’s Trodelvy for two indications
26d ago
MRK
GILD
Gilead announces EC grants marketing authorization for Trodelvy
Premium
The Fly
Gilead announces EC grants marketing authorization for Trodelvy
28d ago
GILD
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
Premium
Market NewsSponsored
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
1M ago
GILD
JAZZ

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >